MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jpainsymman.2017.07.033

Медицинская библиотека · Journal of pain and symptom management · 2017

Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.

Griffith Kathleen A, Zhu Shijun, Johantgen Meg, Kessler Michael D, Renn Cynthia, Beutler Andreas S, Kanwar Rahul, Ambulos Nicholas, Cavaletti Guido, Bruna Jordi, Briani Chiara, Argyriou Andreas A, Kalofonos Haralabos P, Yerges-Armstrong Laura M, Dorsey Susan G

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

CONTEXT: Oxaliplatin-induced peripheral neuropathy (OIPN) is a dose-limiting toxicity of oxaliplatin and affects most colorectal cancer patients. OIPN is commonly evaluated by patient symptom report, using scales to reflect impairment. They do not discriminate between unique grouping of symptoms and signs, which impedes prompt identification of OIPN.

OBJECTIVE

The objective of this study was to identify clusters of symptoms and signs that differentiated underlying clinical severity and segregated patients within our population into OIPN subgroups.

METHODS

Chemotherapy-naive colorectal cancer patients (N = 148) receiving oxaliplatin were administered the Total Neuropathy Score clinical (TNSc©), which includes symptom report (sensory, motor, autonomic) and sensory examination (pin sense, vibration, reflexes). The TNSc was administered before chemotherapy initiation (T0) and after cumulative doses of oxaliplatin 510-520 mg/m2 (T1) and 1020-1040 mg/m2 of oxaliplatin (T2). Using mean T2 TNSc scores, latent class analysis grouped patients into OIPN severity cohorts.

RESULTS

Latent class analysis categorized patients into four distinct OIPN groups: low symptoms and low signs (n = 54); low symptoms and intermediate signs (n = 44); low symptoms and high signs (n = 21); and high symptoms and high signs (n = 29). No differences were noted among OIPN groups on age, sex, chemotherapy regimen, or cumulative oxaliplatin dose.

CONCLUSION

We identified OIPN patient groups with distinct symptoms/signs, demonstrating variability of OIPN presentation regardless of cumulative oxaliplatin dose. Over half of the sample had positive findings on OIPN examination despite little or no symptoms. Sensory examination of all patients receiving oxaliplatin is indicated for timely identification of OIPN, which will allow earlier symptom management.

Для цитирования: Griffith Kathleen A, Zhu Shijun, Johantgen Meg, Kessler Michael D, Renn Cynthia, Beutler Andreas S, Kanwar Rahul, Ambulos Nicholas, Cavaletti Guido, Bruna Jordi, Briani Chiara, Argyriou Andreas A, Kalofonos Haralabos P, Yerges-Armstrong Laura M, Dorsey Susan G. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.. Journal of pain and symptom management. 2017. DOI: 10.1016/j.jpainsymman.2017.07.033.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.